Overview

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Antibodies, Monoclonal
Nivolumab